Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

f granted, may have significant limitations on its use. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, safety and efficacy data from additional clinical studies may not warrant further development of this compound for the treatment of chronic hepatitis B and completing our clinical studies may take longer or cost more than expected. In addition, feedback from regulatory authorities or results from clinical trials might require modifications or delays in later stage clinical trials or additional trials to be performed. Further, other regulatory authorities may not approve tenofovir DF for the treatment of chronic hepatitis B, and marketing approval, if granted, may have significant limitations on its use and physicians and may not see advantages of tenofovir DF over other treatment options and may therefore be reluctant to prescribe tenofovir DF for chronic hepatitis B. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Report on Form 10-Q for the first quarter of 2007, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Hepsera and Viread are registered trademarks of Gilead Sciences, Inc.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

Contact

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (M
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/26/2015)... 2015 "Whether it,s our family, our friends, ... In a single sentence, Dr. Anthony Coyle ... Pfizer,s Centers for Therapeutic Innovation (CTI), sums ... at America,s biopharmaceutical companies. CTI,s unique ... patient foundations and the National Institutes of Health (NIH) ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... , March 26, 2015 When ... by their existing PACS vendor their system would ... determined that they needed a better structured solution ... selected Avreo interWORKS due to its interface capabilities ... meaningful use standards through to the hospital,s radiology ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... at Food and Drug Administration Meeting , ... WASHINGTON , July 20 ... and treating disease, representatives of the College of American Pathologists (CAP) ... increased oversight of laboratory developed tests (LDTs) and "direct-to-consumer" tests. Most ...
... SHENZHEN, China , July 20 /PRNewswire-Asia-FirstCall/ -- China Nepstar,Chain ... largest,drugstore chain in China based on the number of directly ... card. , , , ... Beginning in May 2010 , Nepstar started to expand its ...
Cached Medicine Technology:CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 2China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 3China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 4
(Date:3/28/2015)... (PRWEB) March 28, 2015 Lately the ... media regarding recent changes and proposals around the NCAA. ... current and former collegiate student-athletes across a spectrum of ... reflect on common challenges. The special panel consists of ... in sports ranging from football, track and field, baseball, ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... City, Mo (PRWEB) March 27, 2015 ... complications for patients undergoing percutaneous coronary intervention (PCI), ... studies have observed a “risk-treatment paradox,” in which ... gain from treatment are treated less often with ... Researchers at Saint Luke’s Mid America Heart Institute ...
(Date:3/27/2015)... 27, 2015 The report “CountryFocus ... an essential source of information on and analysis ... Germany. Germany’s increasingly elderly population and its associated ... market. In 2013, the elderly accounted for 27.1% ... Compound Annual Growth Rate (CAGR) of 1.2% to ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4
... issue of the Journal of Periodontology (JOP) found that smokers ... than non-smokers. , The study followed 10 smokers and 10 ... smoke on the long term outcomes of a treatment to ... teeth. After two years, residual gum recession around the ...
... in APO gene not warranted, researchers say , , TUESDAY, Sept. ... are not as important an indicator of coronary risk as ... previously published studies. , The APO gene comes in three ... gene produce a protein that is an important component of ...
... Sept. 18 Eli Lilly and Company,(NYSE: ... M.D., Ph.D., F.R.C.P.,will join Lilly in January, 2008, ... division responsible for development of Lilly,s,expanding diabetes and ... Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who ...
... 18 Christina Economos, PhD,principal investigator of Shape Up ... to curb childhood obesity, will present,her research at the ... 31st in Boston. "Shape Up Somerville" was a ... third graders in the culturally diverse Boston,suburb of Somerville, ...
... Quality Forum (NQF) and The Joint Commission today announced the,2007 ... Quality,Awards. Honorees were selected in all four award categories., ... ACHIEVEMENT (2 RECIPIENTS), -- Flaura Koplin Winston, M.D., Ph.D. ... Prevention at The Children,s Hospital of Philadelphia and the ...
... today that it has received an award of more ... the Johns Hopkins Institute for Clinical and Translational Research ... Hopkins researchers to hasten and improve the process of ... and eventually to the community. , This grant ...
Cached Medicine News:Health News:Study Downgrades Gene as Heart Risk Factor 2Health News:Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division 2Health News:Success of 'Shape-Up Somerville' Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 3Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 4Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 5Health News:Johns Hopkins receives $100 million grant to speed research from clinic to community 2
... Reposable system components for creating each access port are ... is packaged sterile together with either a 5 mm ... needle is packaged non-sterile; 5 mm, 7/8 mm, ... 5 mm, 7/8 mm, 10 mm and 12 ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Medicine Products: